http://www.pfizer.com/are/investors_report...08_09_10_11.htm
"Yet many eyes are on the newest aromatase inhibitor, Pfizer’s Aromasin. Currently approved for advanced metastatic disease, Aromasin differs from its two competitors in how it blocks an enzyme that produces estrogen. It is also unique in acting as a weak male hormone, which may help control breast cancer and protect or even promote bone density. (Anastrazole and letrozole are linked to more clinical fractures.)
"Emerging data suggest that Aromasin possesses both a therapeutic advantage for treating breast cancer and also a general women’s health advantage," says Dr. Paul Goss of Toronto’s Princess Margaret Hospital, architect and leader of the letrozole trial. "That’s why Aromasin is the key drug in all imminent hormonal therapy trials under way in early-stage breast cancer." Goss is leading key Aromasin trials in early breast cancer and breast cancer prevention."
So...seems like some data is leaking out. Maybe someone can press Dr. Goss for details?